Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Optum and MarinHealth form strategic partnership

MarinHealth Medical Center has become the latest health system to form a strategic relationship with Optum, announcing a partnership to advance its operational objectives in the revenue cycle and facilitate the patient experience for people living in Marin County, California.

Optum and MarinHealth will focus on operational efficiency for the health system, the organizations said. To do this, MarinHealth will employ Optum technology to streamline nonclinical administrative processes and simplify experiences for patients and providers. Optum also will provide revenue cycle management services and supporting technologies.

MarinHealth hopes the relationship will equip it with the necessary tools and resources to improve business processes and enhance infrastructure. Its goal is to remain an independent health system, with the newfound operational and administrative support allowing doctors and nurses to focus more on patient care.

Source: Healthcare Finance

https://www.healthcarefinancenews.com/news/optum-and-marinhealth-form-strategic-partnership

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!